Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Approval symbols : VTRS save search
Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -1.34%
OCUP | News | $1.53 1.33% 1.31% 140K
|
Health Technology
|
| O: 0.75%
H: 3.46%
C: -6.67%
fda pharma approval ryzumvl
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Published: 2023-09-27 (Crawled : 12:00) - globenewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 0.0%
H: 1.03%
C: -1.34%
OCUP | News | $1.53 1.33% 1.31% 140K
|
Health Technology
|
| O: 0.75%
H: 3.46%
C: -6.67%
fda pharma approval treatment eye ryzumvl
Viatris Announces U.S. FDA Tentative Approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), a Once-daily Treatment for Children Living with HIV
Published: 2023-09-05 (Crawled : 09:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 0.0%
H: 0.88%
C: -1.58%
fda tentative children approval treatment hiv living
Revance Announces FDA Approval of DAXXIFY™ (DaxibotulinumtoxinA-lanm) for Injection, the First and Only Peptide-Formulated Neuromodulator With Long-Lasting Results
Published: 2022-09-08 (Crawled : 18:00) - biospace.com/
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -0.57%
H: 0.83%
C: 0.16%
RVNC | $3.665 0.69% 0.68% 1.6M
|
Health Technology
|
| O: 18.79%
H: 3.03%
C: 2.35%
fda approval
Viatris Inc. Announces Receipt of the First FDA Approval for Generic Version of Symbicort® Inhalation Aerosol, Breyna™ (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in Partnership with Kindeva
Published: 2022-03-16 (Crawled : 12:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 1.46%
H: 3.86%
C: 2.82%
symbicort fda partnership fda approval approval
Viatris is First to Receive FDA Approval of Generic Restasis® (Cyclosporine Ophthalmic Emulsion 0.05%) to Treat Dry Eye Disease
Published: 2022-02-03 (Crawled : 23:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -1.05%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -2.48%
H: 0.0%
C: 0.0%
restasis dry eye fda eye fda approval eye disease approval disease ophthalmic emulsion
Viatris Inc. and Biocon Biologics Receive Historic Approval for First Interchangeable Biosimilar Semglee® (insulin glargine-yfgn injection) for the Treatment of Diabetes
Published: 2021-07-29 (Crawled : 04:00) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: 2.88%
H: 0.27%
C: -2.39%
diabetes treatment injection insulin approval biosimilar glargine
Viatris Inc. and Kindeva Drug Delivery Announce FDA Tentative Approval of the First Abbreviated New Drug Application Generic Version of Symbicort® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol
Published: 2021-03-08 (Crawled : 12:10) - prnewswire.com
VTRS | News A | $11.36 0.98% 0.97% 4.7M
|
Health Technology
|
| O: -1.08%
H: 2.11%
C: 0.51%
new drug fda drug drug delivery liver approval
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.